Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

MMI to expand study of robotic microsurgery for Alzheimer's

1 August 2026 · By · Wire by Fusion42

Published

1 August 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 1 August 2026 · Fusion42 review

The FDA has approved MMI to expand enrollment in its feasibility trial using the Symani robotic system for microsurgery aimed at restoring lymphatic drainage in Alzheimer's patients.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

FDA clearance to expand patient enrollment in a robotic microsurgery trial opens new opportunities for you in medtech trials focused on neurodegenerative diseases. Prepare to engage clinical partners and adapt development plans to leverage this regulatory momentum.

◆ Coverage

1 source · 1 Aug 2026

◆ Related on Wire

◆ Topics

Medtechrobotic-microsurgeryalzheimersFDAclinical-trialmedtech